According to data from a murine model and clinical data from 15 patients with HCC, the combined administration of IFN-α and PD-L1 blockades led to notable tumor regression, providing promising evidence for the translational and clinical application of this combination treatment [11]. Here, CD274 is linked to neoplasm.